Safety of epicutaneous immunotherapy for the treatment of peanut allergy: A phase 1 study using the Viaskin patch

J Allergy Clin Immunol. 2016 Apr;137(4):1258-1261.e10. doi: 10.1016/j.jaci.2016.01.008. Epub 2016 Feb 24.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Letter
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Cutaneous
  • Adolescent
  • Adult
  • Child
  • Desensitization, Immunologic / adverse effects
  • Desensitization, Immunologic / instrumentation
  • Desensitization, Immunologic / methods*
  • Double-Blind Method
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Patient Compliance
  • Peanut Hypersensitivity / therapy*
  • Treatment Outcome
  • Young Adult

Associated data

  • ClinicalTrials.gov/NCT01170286